Galectin Therapeutics (GALT) Tops Q1 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Tractor Supply and Starlink team up to expand rural broadband via 4-H
• Macquarie Downgrades Luk Fook Holdings International Ltd. (590:HK) (LKFLF) to Neutral